Investors purchased shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Wednesday. $95.30 million flowed into the stock on the tick-up and $76.49 million flowed out of the stock on the tick-down, for a money net flow of $18.81 million into the stock. Of all equities tracked, Eli Lilly and had the 19th highest net in-flow for the day. Eli Lilly and traded down ($0.95) for the day and closed at $80.55

LLY has been the subject of a number of research analyst reports. BMO Capital Markets reduced their price objective on shares of Eli Lilly and from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, April 12th. Vetr cut shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating and set a $85.08 price objective for the company. in a research report on Monday, April 18th. Credit Suisse Group AG reaffirmed an “overweight” rating on shares of Eli Lilly and in a research report on Tuesday, April 26th. Leerink Swann reduced their price objective on shares of Eli Lilly and from $101.00 to $96.00 and set an “outperform” rating for the company in a research report on Monday, May 2nd. Finally, Jefferies Group reissued a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a report on Friday, May 13th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $95.90.

The stock has a market cap of $85.20 billion and a P/E ratio of 34.72. The firm has a 50 day moving average of $79.92 and a 200-day moving average of $75.94.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting the consensus estimate of $0.86. During the same quarter in the prior year, the business earned $0.90 EPS. The company earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Co. will post $3.59 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be paid a $0.51 dividend. The ex-dividend date is Thursday, August 11th. This represents a $2.04 annualized dividend and a yield of 2.53%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $75.12, for a total value of $15,024,000.00. Following the sale, the insider now owns 127,090,804 shares of the company’s stock, valued at approximately $9,547,061,196.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Melissa S. Barnes sold 992 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $73.77, for a total value of $73,179.84. Following the completion of the sale, the senior vice president now directly owns 10,710 shares in the company, valued at approximately $790,076.70. The disclosure for this sale can be found here.

Several hedge funds have added to or reduced their stakes in the stock. TCI Wealth Advisors Inc. boosted its stake in Eli Lilly and by 0.5% in the fourth quarter. TCI Wealth Advisors Inc. now owns 14,349 shares of the company’s stock valued at $1,209,000 after buying an additional 76 shares during the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in Eli Lilly and by 1.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 20,579 shares of the company’s stock valued at $1,734,000 after buying an additional 239 shares during the last quarter. FineMark National Bank & Trust boosted its stake in Eli Lilly and by 0.9% in the fourth quarter. FineMark National Bank & Trust now owns 26,392 shares of the company’s stock valued at $2,223,000 after buying an additional 246 shares during the last quarter. Homrich & Berg boosted its stake in Eli Lilly and by 1.9% in the fourth quarter. Homrich & Berg now owns 16,855 shares of the company’s stock valued at $1,420,000 after buying an additional 317 shares during the last quarter. Finally, Palladium Partners LLC boosted its stake in Eli Lilly and by 0.4% in the fourth quarter. Palladium Partners LLC now owns 152,214 shares of the company’s stock valued at $12,826,000 after buying an additional 531 shares during the last quarter.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.